Introduction: Nuclear factor kappa B/p65 (NF-jB/p65) regulates the expression of various molecules important in tumorigenesis as cyclooxygenase-2 (COX-2).
Introduction
Lung cancer is the leading cause of death worldwide. The nonsmall cell lung cancer (NSCLC) accounts for 75-85% among all lung cancers. The conventional treatment e.g. surgery, radiotherapy and chemotherapy yields a dismal overall 5-year survival of 14% which necessitates the development of new treatment options [1] .
An interesting implication for the presence of high levels of nuclear factor kappa-B (NF-jB)/p65 expression in epithelial tumors such as lung cancer is the finding reported from several in vivo and in vitro studies that NF-jB inhibits chemotherapyinduced apoptosis of tumor cells by regulating either directly or indirectly the transcription of several genes whose protein products have an antiapoptotic effect [2] . In particular, p65 activation is a predictive factor of resistance to neoadjuvant chemotherapy in breast cancer patients [3] .
The most common form of NF-jB is a heterodimer consisting of p65 and p50. In most quiescent normal cells; the NF-jB dimers are bound with and kept in the cytoplasm by inhibitor of NF-jB that mask the nuclear localization sequence (NLS) in the NF-jB proteins [4] .
NF-jB regulates the expression of various molecules important in tumorigenesis, such as matrix metalloproteinases, cyclooxygenase-2 (COX-2), iNOS, chemokines, and inflammatory cytokines, all of which promote tumor cell invasion and angiogenesis [5] .
With advances in cytogenetic and molecular biology, the detection and analysis of tumor suppressor genes and oncogenes may provide predictive values for prognosis and treatment choice for NSCLC. Among these molecular markers, COX-2 over expression is common in NSCLC [6] .
Cyclooxygenase-2 is an inducible enzyme that can be activated by cytokines, growth factors, oncogenes and chemical carcinogens. COX-2 is related to inflammation and carcinogenesis. It has been shown that COX-2 contributes to carcinogenesis by increasing the angiogenesis and invasiveness, and inhibiting apoptosis. The carcinogenic effect of COX-2 is mainly exerted through the increase of prostaglandin levels e.g. PGE2 [7] . COX-2 inhibitor has been investigated in both pre-clinical and clinical studies, and has shown synergistic effects with radiation and chemtoxic drugs on tumor [1] .
Aim of the work
To study the immunohistochemical expression of NF-jB/p65 protein and COX-2 in NSCLC patients, investigate the relationship between their expression and the clinicopathological parameters, evaluate their prognostic value and clarify their impact on survival in such patients.
Patients and methods

Patients
This study was carried out on 50 cases of NSCLC and 20 normal bronchial mucosal biopsies taken from the same patients (as control) at Chest and Clinical Oncology Departments, Tanta university hospital and the patients were treated and followed up during the period from December 2010 to April 2013. Written, informed consent was obtained from each patient before enrollment into the study.
All patients were subjected to the following:
(1) Complete medical history and physical examination including a full neurologic examination, documentation of the Eastern Cooperation Oncology Group (ECOG) performance and weight loss. (2) Routine laboratory tests: complete blood picture, liver, kidney functions and biochemical testing (3) Plain chest X ray postero-anterior view. (4) Spirometry. (5) CT chest with contrast (peripheral tumors were diagnosed by CT guided biopsy and sent for histopathological examination). (6) Fiberoptic bronchoscopy for inspection of the tracheobronchial tree for vocal cord paralysis, subcarinal widening for staging, and biopsy taking.
The fiberoptic bronchoscopy (Model: Olympus BF type P10, Tokyo, Japan) was done for diagnosis of central tumors as follows:
After fasting overnight, premedications were taken in the form of 0.6 mg atropine sulfate intramuscular 30 min before the procedure. Xylocaine spray 10% was used for local anesthesia for upper airways. It was done via nasal route; Xylocaine solution 2% was used to anesthetize vocal cords, trachea and lower airways. Visible tumor was biopsied, also multiple endobronchial biopsies were taken from the other side of the bronchial tree (as control); any biopsy with proved dysplastic changes was discarded. The biopsies were obtained by forceps under direct vision, carefully removed and placed in 10% formaline fixative. (7) Histopathological study: using hematoxylin and eosin staining for routine evaluation of the histopathological characteristics and grading of the studied tumors. (8) Immunohistochemical study: 3 lm sections were deparaffinized in xylene for 30 min and rehydrated with graded alcohol series. Sections were then subjected to antigen retrieval by boiling the tissue sections in 10 mM citrate buffer, pH 6.0 (Lab Vision catalog # AP-9003), for 10 min followed by cooling at room temperature for 20 min and rinsing with phosphate buffered saline (PBS) for one minute. Endogenous peroxidase was blocked by immersion of the sections in 3% hydrogen peroxide solution for 10 min, then washing them in PBS. Immunohistochemical staining was performed using the UltraVision Detection Kit (TP-015-HD, Lab Vision, USA) according to the manufacturer's protocol. Sections were incubated for 10 min with Ultra V block to prevent non-specific background staining, followed by rinsing the sections with PBS. Afterward, an overnight incubation was done in a humidity chamber with rabbit monoclonal anti-COX-2 antibody (Clone SP21, Cat. No. RM-9121-R7, Ready to use, Lab Vision), and rabbit polyclonal anti-NFkB/p65 (Rel A) Ab-1 antibody (Cat. No. RB-1638-R7, Ready to use, Lab Vision), followed by washing in PBS.
Sections were then covered with 4-5 drops of UltraVision biotinylated goat anti-polyvalent secondary antibody, incubated at room temperature for 10 min, then washed in PBS, followed by incubation with streptavidin peroxidase solution for 10 min at room temperature, then rinsing with PBS. Sections were then covered for 15 min by adding one drop of 3-3 0 -diamino-benzidine-tetra-hydrochloride (DAB) chromogen mixed with 2 ml of DAB substrate. Finally, sections were counterstained with Mayer's hematoxylin, dehydrated in alcohol and mounted in di-n-butyl-phthalate-polystyrene-xylene (DPX). As positive controls, sections from a case of colonic carcinoma known to show over-expression of COX-2 antibody, and sections from a case of prostatic carcinoma known to show over-expression of NF-jB/p65 antibody were used. Negative controls were prepared by omission of the primary antibodies.
Immunohistochemical evaluation and scoring
COX-2 expression was evaluated semiquantitatively according to the gross percentage of cells demonstrating a distinct cytoplasmic immunohistochemical reaction. [8] The immunostained samples were scored to display absent (0), weak (+), moderate (++), or strong (+++) immunoreactivity [9] .
Positivity of the tumor for NF-jB expression was defined as only distinct nuclear immunostaining, which is considered as activated NF-jB [10] .
Nuclear localization of NF-jB was categorized as positive or negative, as well as an overall proportion of cells (<1%, 1-10%, and >10%) with positive nuclear staining in the studied field at 100 magnification. A minimum of five different areas for each specimen was evaluated, and the mean was assessed [11] .
(9) Patients underwent computed tomographic scans of the abdomen, magnetic resonance imaging of the brain and radionuclide bone scans were performed when clinically indicated. Each patient had a performance status of 2 or lower on the ECOG scale and adequate hematologic parameters were included in this study.
The clinical and pathological staging was determined according to the international staging system [12] and accord-ingly standard treatment protocols and follow up schedules based on published guidelines were selected [13] .
Statistical analysis
The data were analyzed using SPSS 13.0 software package. The correlation of NF-jB and COX-2 expression with different clinicopathologic characteristics was analyzed with chisquare test. The Kaplan-Meier method and Log-rank test were used to analyze the correlation of patient survival with NF-jB and COX-2 expression. Overall-survival was defined as the time from diagnosis to the date of death from any cause or last follow-up. A significance level of P < 0.05 was used.
Results
In the fifty patients who were enrolled in this study; only three out of 20 patients with early stage disease (stages I, II, IIIA) underwent lobectomy while the remaining were medically inoperable or refused surgery. Nine patients were assigned to receive thoracic radiotherapy alone. Seventeen patients received concurrent carboplatin/paclitaxel and thoracic radiotherapy. While the majority of patients ( [21] ; stage IV) received chemotherapy alone in the form of platinum-based chemotherapy for advanced and metastatic diseases with palliative radiotherapy for metastatic sites; no one received neoadjuvant chemotherapy or radiotherapy. The median follow up of patients was 13 months (range 4-22 months).
There were 29 (58%) out of 50 cases of NSCLC who were diagnosed as adenocarcinoma, 13 (26%) cases as squamous cell carcinoma, and 8 (16%) cases as large cell carcinoma.
Thirty six cases (72%) showed positive NF-jB/p65 expression (23 adenocarcinomas (46%), 8 squamous cell carcinomas (16%), and 5 large cell carcinomas (10%)). Eighteen cases (36%) showed positive expression in >10% ( Figs. 1 and 2 ), 10 cases (20%) in 1-10% (Fig. 3) , and 8 cases (16%) in <1% of tumor cells. On the other hand, 14 cases (28%) showed negative expression for NF-jB/p65 ( Table 1) .
The NF-jB/p65 expression in NSCLC was significantly correlated with more advanced tumor stage (stages III and IV) and lymph node metastasis ( Table 1) . The NF-jB/p65 expression in squamous cell carcinoma and adenocarcinoma was higher than that in the normal lung tissue (P < 0.01); and the NF-jB/p65 expression in adenocarcinoma was higher compared to that in squamous and large cell carcinomas (P < 0.01).
NF-jB/p65 expression was significantly related to the patients' age, sex, smoking, histopathological type, tumor grade, tumor stage and performance status (P < 0.05).
The median survival time was 17.27, 16 and 7 months for 1%, 1-10% and >10% NF-jB positive patients respectively; whereas the survival time was 17.77 months for patients with NF-jB negative expression with a significant correlation ( Fig. 4) .
Forty five cases (90%) showed positive COX-2 expression (29 adenocarcinomas (58%), 10 squamous cell carcinomas (20%), and 6 large cell carcinomas (12%)). Twenty one cases (42%) showed (+++) expression (Figs. 5 and 6), 13 cases (26%) showed (++) expression ( Fig. 7 ) and 11 cases (22%) showed (+) expression. On the other hand, 5 cases (10%) showed negative COX-2 expression. No expression of COX-2 was detected in normal lung tissue. COX-2 expression in NSCLC patients significantly correlated with advanced tumor stage (stages III and IV) and lymph node metastasis ( Table 2 ).
All the studied cases of adenocarcinoma (100%) showed positive COX-2 expression, which was significantly higher than that in squamous and large cell carcinomas (P < 0.01).
COX-2 expression was significantly related to the patients' sex, histopathological type, tumor grade, tumor stage, nodal metastasis and performance status (P < 0.05).
The median survival time was 15.09, 15.86 and 11 months for (+), (++) and (+++) COX-2 positive patients respectively whereas the survival time was 15.670 months for patients with COX-2 negative expression with no significant correlation (Fig. 8) .
A significant positive relationship was found between COX-2 and NF-jB/P65 immunohistochemical expression in NSCLC (X 2 = 58.682, P = <0.001) ( Table 3 ).
Discussion
The p65 subunit of NF-jB is responsible for the transactivation of downstream genes involved in the regulation of cell survival, cell cycle distribution, and apoptosis [14] . Wang et al. [15] concluded that p65 expression has a protective role against celecoxib-mediated cell death of human breast cancer.
There is a close relationship between the transcription factor NF-jB and regulation and control of cellular proliferation
Survival Functions
Overall survival and tumorigenesis [16] . NF-jB is also implicated in cancer development and progression [17] .
Tumor cells often use NF-jB to achieve resistance to anticancer drugs and radiation; inhibition of NF-jB activation appears as a promising option to improve the efficacy of conventional anti-cancer therapies [18] .
In the present study, there were 36 cases; 72% showed positive NF-jB/p65 expression. In agreement with our findings, Tang et al. 2006 [19] found high levels of NF-jB/p65 nuclear expression in the majority (54%) of NSCLCs which warrants the evaluation of this marker as a predictor of chemotherapy or radiotherapy response in lung cancer. Another study also evaluated the expression of NF-jB in 71 specimens from NSCLC patients and showed that nuclear positive rate was 67.6% [20] .
In this study, NF-jB/p65 expression in NSCLC significantly correlated with advanced tumor stage (stages III and IV) and lymph node metastasis. In accordance with the present study, Tang et al. [19] found that NF-jB/p65 expression in lung adenocarcinomas significantly correlated with more advanced tumor stage (stages III and IV) and, in particular, locally advanced tumors and lymph node metastasis.
Tumor-induced activity of COX-2 and related downstream enzymes e.g. PGE2 has been implicated to play a crucial role to enhance tumor invasion and metastasis, angiogenesis, decreased host immunity, and resistance to apoptosis [9] .
The tumor-associated upregulation of COX-2 expression may be regarded as a particular feature of tumorigenesis and development of an invasive type of NSCLC correlating with high levels of COX-2 expression in lymph node metastases of human lung tumors [21] .
The current study, in accordance with multiple published reports [1, 7, 9, [22] [23] [24] demonstrate an increased expression of COX-2 in NSCLC, particularly in adenocarcinomas; which was significantly higher compared to its expression in squamous cell and large cell carcinomas. This might provide a basis for applying COX-2 inhibitor in adenocarinoma patients. In agreement with this study; Li et al. [1] found significant COX-2 expression in NSCLC than normal lung tissue (0%). The present study could not detect a correlation between COX-2 expression and survival; this is in agreement with Turk et al. and Marrogi et al. [7, 25] .
It has been reported that non steroidal anti-inflammatory drugs (NSAID) increase the cytotoxic effect of the radiotherapy and chemotherapy [26] . In clinical studies, celecoxib, a selective COX-2 inhibitor, has increased the response rate of paclitaxel and carboplatine administered preoperatively in the NSCLC patients [27, 28] .
In a phase II study by Edelman et al. [29] survival was significantly better when COX-2 inhibitor celecoxib was added to the chemotherapy compared to chemotherapy only in advanced stage NSCLC patients showing increased COX-2 expression. Fidler et al. [30] also reported a better survival in lung cancer patients with COX-2 overexpression treated with second line decotaxel and celecoxib compared with the patients without COX-2 expression. In these patients with poor prognosis, COX-2 expression can be a target for treatment. Furthermore, selective COX-2 inhibitors have the potential to inhibit tumor angiogenesis and metastasis and can be used for long-term maintenance treatment.
Like the results of this study, Zhang et al. [20] found that the expression level of NF-jB in poorly or moderately differentiated lung cancer cells was higher than that in well-differentiated ones.
In a study of Jianqun et al. [31] there was a high expression of NF-jB in the poorly-differentiated lung cancer cells (28 cases), and a low expression in the well-differentiated lung cancer cells (17 cases), t = 3.640, P = 0.001 which might also be one of the reasons for NSCLC tolerance to chemotherapy and poor prognosis.
This study showed that the NF-jB expression in squamouscell carcinoma and adenocarcinoma was higher than that in normal lung tissue; and the NF-jB expression in adenocarcinoma was higher compared to that in quamous-cell carcinoma, this is in agreement with the study of Zhang et al. [32] .
The NF-jB/p65 was significantly related to the patients' age, sex, smoking, histopathological type, tumor grade, tumor stage and performance status (P < 0.05). Cigarette smoke condensate induced the expression of the NF-jB-regulated proteins COX-2 and celecoxib abolished the induction, this explains the relation between NF-jB and smoking [5] . In contrast, Jianqun et al. [31] found that NF-jB was not related to the patients' age, gender, stage, size and site of the tumor, or pathological type, P > 0.05.
Zhang et al. [20] concluded that immunohistochemical expression NF-jB in patients with NSCLC was an independent prognostic factor for overall survival; this is in agreement with this study. On the other hand, Tang et al. [19] concluded that there was no correlation detected between NF-jB/p65 expression and overall survival.
In this study, a significant positive relationship was found between COX2 and NF-jB immunohistochemical expression in NSCLC, this is in accordance with the study published by Zhang et al. [20] This can be explained by the fact that NF-jB activation directly exerts transcriptional regulation of COX-2 [19] .
Conclusion
NF-jB/P65 and COX2 expression has a prognostic value in NSCLC and they are suitable targets for the development of new lung cancer therapies. It is assumed that inhibition of NF-jB and COX-2 will augment the efficacy of anticancer therapy.
Survival Functions
Overall survival Table 3 Relationship between COX-2 and NF-jB/p65 immunohistochemical expression in non-small cell lung cancer.
NF-jB n (%)
COX-2 n (%) Negative (+) (++) (+++) Negative 5 (10%) 6 (12%) 3 (6%) 0 (0%) 1% 0 (0%) 3 (6%) 5 (10%) 0 (0%) 1-10% 0 (0%) 2 (4%) 4 (8%) 4 (8%) >10% 0 (0%) 0 (0%) 1 (2%) 17 (34%) Chi-square X 2 58.682 P-value <0.001 X 2 : Chi square.
